ALK7 and myostatin inhibitors and uses thereof

Details ALK7 and myostatin inhibitors and uses thereof ALK7 and myostatin inhibitors and uses thereof

2005-03-02

2008-11-25

Kemmerer, Elizabeth C. (Department: 1646)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S012200, C424S133100, C424S178100, C435S069700

Reexamination Certificate

active

07456149

ABSTRACT:
The invention relates to ALK7 soluble receptors and their uses as antagonists of the function of certain ligands such as GDF-8 (Myostatin) and GDF-11. The ALK7 soluble receptor of the invention is useful as antagonists of GDF-8 and GDF-11 in the treatment of neuronal diseases or conditions such as stroke, spinal cord injury, and all peripheral nerve diseases. The ALK7 soluble receptor of the invention is also useful as GH (growth hormone) equivalent, and for increasing muscle mass.

REFERENCES:
patent: 5538892 (1996-07-01), Donahoe et al.
patent: 5614609 (1997-03-01), Ibanez et al.
patent: 5789565 (1998-08-01), Ibanez et al.
patent: 5811245 (1998-09-01), Ibanez et al.
patent: 5891638 (1999-04-01), Ibanez et al.
patent: 5976815 (1999-11-01), Ibanez et al.
patent: 6162896 (2000-12-01), Mathews et al.
patent: 6368597 (2002-04-01), Strassmann et al.
patent: 6818440 (2004-11-01), Plowman et al.
patent: 2004/0219139 (2004-11-01), Plowman et al.
patent: 2004/0234540 (2004-11-01), Plowman et al.
patent: 2005/0026184 (2005-02-01), Plowman et al.
patent: 2003113111 (2003-04-01), None
patent: WO-96/12805 (1996-05-01), None
patent: WO 98/49317 (1998-11-01), None
patent: WO 02/085306 (2002-10-01), None
patent: WO 03/027248 (2003-04-01), None
patent: WO 03/072714 (2003-09-01), None
patent: WO 2004/108157 (2004-12-01), None
Whittemore et al., Jan. 2003, Biochemical and Biophysical Research Communications 300:965-971.
Massague, 1998, Annu. Rev. Biochem. 67:753-791.
Kirsch et al., 2000, Nature Structural Biology 7:492-496.
Bondstam, et al., “cDNA Cloning, Expression Studies and Chromosome Mapping of Human Type I Serine/Threonine Kinase Receptor ALK7 (ACVR1C),” Cytogenetics and Cell Genetics, 95(3-3:157-162 (2001).
Reissmann, et al., “The Orphan Receptor ALK7 and the Activin Receptor ALK4 Mediate Signaling by Nodal Proteins During Vertebrate Development,” Genes & Development, 15(15):2010-2022 (2001).
Roberts, et al., “Identification of Novel Isoforms of Activin Receptor-Like Kinase 7 (ALK7) Generated by Alternative Splicing and Expression of ALK7 and Its Ligand, Nodal, in Human Placenta,” The Society for the Study of Reproduction, Inc. 68(5):1719-1726 (2003).
Ryden, et al., “A Novel Type I Receptor Serine-Threonine Kinase Predominantly Expressed in the Adult Central Nervous System,” The Journal of Biological Chemistry, 271(48): 30603-30609 (1996).
Tsuchida, et al., “Activin Isoforms Signal Through Type I Receptor Serine/Threonine Kinase ALK7,” Molecular and Cellular Endocrinology 220:59-65 (2004).
Tsuchida, et al., “Molecular Cloning of a Novel Type I Receptor Serine/Threonine Kinase for the TGF β Superfamily from Rat Brain,” Department of Molecular Genetics 7(6):467-478 (1996).
Greenwald, et. al., “The BMP7/ActRII Extracellular Domain Comples Provides New Insights into the Cooperative Nature of Receptor Assembly,” Molecular Cell, 11, 605-617 (2003).

Affiliated with

Also associated with

Rating

ALK7 and myostatin inhibitors and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with ALK7 and myostatin inhibitors and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and ALK7 and myostatin inhibitors and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4034230